T4DM
Testosterone for the Prevention of Type 2 Diabetes Mellitus (Wittert et al., Lancet Diabetes & Endocrinology 2021)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
1 human trial, about 1 studies, 1,007 participants men aged 50-74 with prediabetes/early T2DM. The written rationale for this grade is still being prepared.
- FDA
- Investigator-initiated RCT (prevention indication, not approved)
Reference only. Not medical advice.
What can go wrong
Hematocrit increased significantly more with testosterone, with a meaningful number of men exceeding the 54% safety threshold and needing intervention. Long-term cardiovascular safety of using testosterone this way is not established by a 2-year glucose trial.
This is something to take to a clinician. The Atlas can tell you what is known about t4dm in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
T4DM was a large randomized, double-blind, placebo-controlled trial in Australia testing whether long-acting injectable testosterone undecanoate, added to a lifestyle program, prevents or reverses type 2 diabetes in men aged 50-74 with impaired glucose tolerance or newly diagnosed diabetes and low-normal testosterone. Over two years in roughly 1,007 men, testosterone reduced the proportion with diabetes on a glucose tolerance test versus placebo. It is the strongest evidence that testosterone affects glucose metabolism, but it was a prevention study in men who were largely not classically hypogonadal, and it raised hematocrit notably.
The trial showing testosterone plus lifestyle reduced type 2 diabetes incidence - with caveats.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone improves insulin sensitivity and body composition (more lean mass, less fat). T4DM tested whether, layered onto lifestyle change, this translates into measurably fewer men crossing the diabetes threshold on an oral glucose tolerance test.
Prevention is not a license for treatment
T4DM enrolled men selected for metabolic risk, not for symptomatic hypogonadism - their low-normal testosterone was often a consequence of obesity. The trial shows a pharmacologic glucose effect, but it does NOT establish testosterone as a frontline diabetes drug, it required injections plus a lifestyle program, and the durability of benefit after stopping is unknown. The raised hematocrit is a real safety cost.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
Replacement is not the same as a cycle
T4DM used standard replacement-dose injectable testosterone undecanoate, not anabolic dosing; even so, hematocrit elevation was a notable, monitorable effect.
What people get wrong
Often saidT4DM means testosterone is a diabetes treatment
ActuallyIt was a PREVENTION trial in prediabetic men, used alongside a lifestyle program, with a glucose-test endpoint - it did not test testosterone as a treatment for established diabetes or against standard diabetes drugs.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Led by Gary Wittert at the University of Adelaide, T4DM was one of the largest and longest randomized testosterone trials ever conducted, published in The Lancet Diabetes & Endocrinology in 2021. It reframed part of the 'low T and metabolic syndrome' debate by showing the relationship is bidirectional and pharmacologically actionable.
- 2013-2017T4DM enrolls and treats 1,007 men over 2 years
- 2021Primary results published in Lancet Diabetes & Endocrinology
What the trials could not show
Limits of the studies themselves, as distinct from limits of the treatment.
- 2-year duration (no long-term or post-cessation data); diabetes defined by OGTT rather than clinical events; participants were metabolically selected, not classically hypogonadal; both arms received lifestyle support (testosterone was add-on); hematocrit elevation; results may not generalize to men with normal testosterone or without obesity.
What we do not know
- Does the glucose benefit persist after stopping testosterone?
- Would it reduce hard diabetes complications, not just OGTT status?
- How does it compare to GLP-1 agonists or metformin for prevention?
At a glance
- Design
- Randomized, double-blind, placebo-controlled, 2 years
- N
- 1,007
- Agent
- Testosterone undecanoate 1000 mg IM at 0, 6 wk, then 3-monthly
- Co-intervention
- Both arms enrolled in a lifestyle program (WW)
- Population
- Age 50-74, waist >=95 cm, IGT or new T2DM, serum T <=14 nmol/L
- Primary outcomes
- 2-hr OGTT glucose >=11.1 mmol/L at 2 years; change in 2-hr glucose
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about T4DM. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
T4DM (Wittert et al., Lancet D&E)2021
At 2 years, diabetes (2-hr OGTT glucose >=11.1 mmol/L) in ~12% of the testosterone group vs ~21% of placebo - a relative reduction of about 40%; greater fat loss and lean-mass gain in the testosterone arm
T4DM hematologic safety2021
Hematocrit rose more in the testosterone group, with more men exceeding 54%, requiring monitoring